Kyverna Therapeutics, Inc. KYTX 深 滬
等待開盤 08-01 09:30:00 美东时间
7.35
-0.140
-1.87%
華盛通- 最 高7.61
- 今 開7.52
- 成交量 35.28万股
- 最 低 7.13
- 昨 收 7.49
- 總市值 4.47亿
- 52周最高 13.67
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 2.80
- 委 比 73.96%
- 總股本 6079.52万
- 歷史最高 35.06
- 量 比 0.47
- 振 幅 6.41%
- 歷史最低 1.78
- 每 手 1
- 風險率 1.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kyverna Therapeutics Announces Manufacturing Agreement For Both U.S. Commercial And Global Clinical Supply Of Miv-Cel, Kyverna’s Autologous CD19-Directed CAR T-Cell Therapy
Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing ...
07-27 20:04
美股大行评级 | 火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元
火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元；犹他美容(ULTA)惨遭12家大行下调目标价>>
06-04 11:36
Kyverna Therapeutics Reports Phase 1 Data For Miv-Cel In Rheumatoid Arthritis, Showing Deep B-Cell Depletion And Potential Immune Reset At Week 36
Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune resetMiv-cel continues to
06-03 20:09
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29
JP Morgan analyst Brian Cheng maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and lowers the price target from $30 to $29.
05-13 23:33
Kyverna Therapeutics Q1 EPS $(0.66) Beats $(0.73) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.73) by 9.59 percent. This is a 35.92 percent increase over losses of $(1.03) per share
05-13 04:40
美股大行评级 | 潜在涨幅15%！15家大行集体上调德州仪器目标价；CSX运输、拉姆研究、金沙集团、马斯可木业、Vertiv Holdings等获多家大行上调目标价
今日重点评级关注：花旗：维持Pegasystems"买入"评级，目标价从70美元升至71美元；巴克莱：维持曼哈顿联合软件"超配"评级，目标价从236美元升至239美元
04-24 12:10
美股夜盘 | FST Corp.涨47.54%，Kyverna Therapeutics, Inc.涨35.84%
FST Corp.涨47.54%；Kyverna Therapeutics, Inc.涨35.84%；Aspire Biopharma Holdings, Inc.涨18.85%
04-22 15:01
美股夜盘 | FST Corp.涨54.92%，Kyverna Therapeutics, Inc.涨42.43%
FST Corp.涨54.92%；Kyverna Therapeutics, Inc.涨42.43%；Aspire Biopharma Holdings, Inc.涨17.63%
04-22 13:01
